drugset / Trial / NCT05698095

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095

Phase 1 Completed 54 enrolled Usona Institute
RandomizedSequentialTriple-blindOther

Summary

The primary objective of the study is to assess the pharmacokinetics, safety, and tolerability of a single-dose and multiple-doses of 5-MeO-DMT administered by intramuscular (IM) injections in healthy subjects.

Timeline

Start
2022-12-27
Primary completion
2023-09-07
Completion
2023-09-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mebufotenin Small molecule 0.5 mg Intramuscular
Subject Mebufotenin Small molecule 2.5 mg Intramuscular
Subject Mebufotenin Small molecule 4.5 mg Intramuscular
Subject Mebufotenin Small molecule 7 mg Intramuscular
Subject Mebufotenin Small molecule 10 mg Intramuscular
Subject Mebufotenin Small molecule 10.5 mg Intramuscular
Subject Mebufotenin Small molecule 13 mg Intramuscular

Indications

No indication recorded.